면역저하 소아에서 발생한 다제내성 녹농균 균혈증을 ceftolozane-tazobactam으로 성공적으로 치료한 증례보고
Treatment of Multidrug-resistant Pseudomonas aeruginosa Bacteremia in a Immunocompromised Child With Ceftolozane-tazobactam
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
최근 광범위 항생제 사용의 증가로 인한 다제내성 그람 음성균의 출현이 전 세계적으로 문제가 되고 있다. 특히 다제내성녹농균(multidrug-resistant Pseudomonas aeruginosa) 감염의 치료는 어려우며 중환자의 사망률을 증가시키는 원인이 된다. 세프톨로잔-타조박탐(ceftolozane-tazobactam, ZerbaxaTM)은 5세대 세팔로스포린과 베타락탐 분해효소저해제로 다제내성 녹농균에 의한 복잡성 요로감염과 복잡성 복강내 감염의 치료에 효과가 있는 것으로 입증되었다. 본지에서 저자들은 소아청소년 혈액암 환자에서 발생한 다제내성 녹농균에 의한 균혈증을 세프톨로잔-타조박탐을 사용하여 성공적으로 치료한 국내 첫 번째 사례를 보고하고자 한다.
Abstract
With the widespread use of broad-spectrum antibiotics in clinical practice, the emergence of multidrug-resistant (MDR) gram-negative bacteria has become a global problem. The MDR Pseudomonas aeruginosa infection is especially difficult to treat and increases mortality in critically ill patients. Ceftolozane-tazobactam (Zerbaxa™) is a fifth-generation cephalosporin and beta-lactamase inhibitor that has proved to be effective for treating complicated urinary tract infections and complicated intra-abdominal infections caused by MDR P. aeruginosa. Herein, we report the first case of pediatric hematologic cancer in Korea that was successfully treated for MDR P. aeruginosa bacteremia with Ceftolozane-tazobactam.
참고문헌 (16)
- "Antimicrobial resistance" (2021)[URL]
- Tackling drug-resistant infections globally : final report and recommendations, "O’Neill J", Government of the United Kingdom, ~ (2016)
- Antimicrobial Resistance Collaborators, "Global burden of bacterial antimicrobial resistance in 2019 : a systematic analysis", Lancet, 399, pp.629~655 (2022)
- Horcajada JP, "Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections", Clin Microbiol Rev, 32, pp.e00031~e00119 (2019)
- Magiorakos AP, "Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria : an international expert proposal for interim standard definitions for acquired resistance", Clin Microbiol Infect, 18, pp.268~281 (2012)
- Cattaneo C, "P. aeruginosa bloodstream infections among hematological patients: an old or new question?", Ann Hematol, 91, pp.1299~1304 (2012)
- Caselli D, "Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation", Haematologica, 95, pp.1612~1615 (2010)
- Tacconelli E, "Discovery, research, and development of new antibiotics : the WHO priority list of antibiotic-resistant bacteria and tuberculosis", Lancet Infect Dis, 18, pp.318~327 (2018)
- Bassetti M, "Treatment of infections due to MDR gram-negative bacteria", Front Med(Lausanne), 6, pp.74~ (2019)
- "IDSA guidance on the treatment of antimicrobial-resistant gram-negative infections: version 1.1" (2022)[URL]
- Karakonstantis S, "Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems", Infection, 48, pp.835~851 (2020)
- Butler MS, "Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections : despite progress, more action is needed", Antimicrob Agents Chemother, 66, pp.e0199121~ (2022)
- Pfaller MA, "Ceftolozane", tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe : report from an antimicrobial surveillance programme(2012-15), 2017, pp.72, 1386~1395
- Zhanel GG, "Ceftolozane", tazobactam : a novel cephalosporin, Drugs, pp.2014, 74[DOI]
- Hakeam HA, "Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens : a multicenter retrospective study", J Infect Public Health, 15, pp.1081~1088 (2022)
- "Product information. Zerbaxa (ceftolozane-tazobactam)" (2022)[URL]